tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Atai Life Sciences price target raised to $16 from $14 at Oppenheimer

Oppenheimer raised the firm’s price target on Atai Life Sciences (ATAI) to $16 from $14 and keeps an Outperform rating on the shares as recent dynamics bode well for BPL-003. As large cap players vie for leadership in neuroscience, psychiatry is increasingly in focus while acquisitions of smaller players are an important source of innovation, Oppenheimer notes.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1